Grufity logoGrufity logo

SRPT

119.29USD+4.72(+4.12%)Delayedas of 28 Nov 2022, 12:36 pm

Sarepta Therapeutics Inc

Market Summary

USD119.29+4.72Delayedas of 28 Nov 2022, 12:36 pm
4.12%

SRPT Alerts

SRPT Stock Price

RSI Chart

Valuation

Market Cap

10.1B

Price/Earnings

-19.93

Price/Sales

12.09

Price/Cashflow

-31.38

MarketCap/EBT

-20.11

Price/Sales

Profitability

EBT Margin

-60.11%

Return on Equity

-69.74%

Return on Assets

-16.91%

Fundamentals

Revenue

Revenue (TTM)

876.0M

Revenue Y/Y

21.57%

Revenue Q/Q

-1.38%

Earnings

Earnings (TTM)

-716.2M

Earnings Y/Y

-435.35%

Earnings Q/Q

-11.34%

Price Action

52 Week Range

61.28123.71
(Low)(High)

Last 7 days

2.3%

Last 30 days

0.2%

Last 90 days

2.4%

Trailing 12 Months

41.5%

Financial Health

Current Ratio

4.53

Investor Care

Shares Dilution (1Y)

0.81%

Diluted EPS (TTM)

-8.22

Peers (Alternatives to Sarepta Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
4.66% 39.76%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
2.35% -50.22%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
0.31% 13.58%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
0.58% 68.05%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
5.82% 12.67%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
17.73% 33.91%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
0.23% 41.48%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-5.94% -0.54%
-18.85
63.29
26.15% -23.38%
3.8B
-
41.63% -30.16%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
-10.09% -56.96%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-10.63% -53.96%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
18.84% 129.95%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
-5.86% -21.13%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
28.14% -69.87%
-1.4
4.57
-43.57% -69.06%
16.0M
-
-12.01% -87.39%
-0.46
19.11
-77.61% 5.14%

Financials for Sarepta Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue4.9%876835766702646
  S&GA Expenses12.0%409365283283291
Earnings Before Taxes-41.5%-710.55-502.03-355.70-418.95-485.54
Net Income-41.4%-716.22-506.63-356.55-418.78-486.12
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets5.3%3,1562,9973,0563,1482,662
  Current Assets6.3%2,6262,4692,5312,6042,185
    Cash Equivalents19.6%1,0398691,2342,1161,599
  Inventory6.3%221208199186288
  Net PPE-1.2%181183187191199
Liabilities20.0%2,7252,2702,1992,2202,193
  Current Liabilities10.5%603546455453373
Shareholder's Equity-40.7%431726857928470
  Retained Earnings-7.3%-3,800.99-3,543.25-3,311.77-3,206.75-3,084.77
  Additional Paid-In Capital2.5%4,2724,1694,1353,554-
Accumulated Depreciation-113----
Shares Outstanding0.3%8888878780
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations18.5%-262.28-321.64-363.98-443.17-588.38
  Share Based Compensation12.6%212189115114114
Cashflow From Investing-0.1%-1,059.26-1,058.11-447.06495374
Cashflow From Financing37.6%771560564562339

Risks

What is the probability of a big loss on SRPT?

84.2%


Probability that Sarepta Therapeutics stock will be more than 20% underwater in next one year

80%


Probability that Sarepta Therapeutics stock will be more than 30% underwater in next one year.

39.2%


Probability that Sarepta Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SRPT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Sarepta Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on SRPT

14.8%


10-Year Cumulative Returns

17.3%


7-Year Cumulative Returns

15.1%


5-Year Cumulative Returns

1.7%


3-Year Cumulative Returns

What are the long-term rolling returns for SRPT?

FIve years rolling returns for Sarepta Therapeutics.

Which funds bought or sold SRPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
2,278
7,000
-%
2022-11-21
FourThought Financial, LLC
-
-
17,000
33,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
4,094,000
12,100,000
0.02%
2022-11-17
M&T Bank Corp
-
-
242,000
747,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
9.13
159,000
419,000
-%
2022-11-16
GLENMEDE TRUST CO NA
NEW
-
243,000
243,000
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
-
-%
2022-11-15
JANE STREET GROUP, LLC
NEW
-
30,182,000
30,182,000
0.01%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-36.56
-1,065,000
15,432,000
0.01%
2022-11-15
Baird Financial Group, Inc.
REDUCED
-22.56
47,000
374,000
-%

1–10 of 38

Latest Funds Activity

Are funds buying SRPT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own SRPT

Sarepta Therapeutics News

InvestorsObserver

Is Sarepta Therapeutics Inc (SRPT) a Good Choice in Biotechnology Monday?.54 minutes ago

SRPT Fair Value

Recent SEC filings of Sarepta Therapeutics

View All Filings
Date Filed Form Type Document
Nov 21, 2022
4
Insider Trading
Nov 21, 2022
4
Insider Trading
Nov 02, 2022
8-K
Current Report
Nov 02, 2022
10-Q
Quarterly Report
Sep 19, 2022
8-K
Current Report
Sep 15, 2022
4
Insider Trading
Sep 14, 2022
4
Insider Trading
Aug 22, 2022
4
Insider Trading

Latest Insider Trading transactions for SRPT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-17
Mayo Stephen
SOLD
-94,311.4
109.92
-858
-
2022-11-17
Rodino-Klapac Louise
SOLD FOR TAXES
-456,978
108.52
-4,211
Head of R&D, CSO
2022-09-14
Chambers Michael Andrew
BOUGHT
5,963,120
104.433
57,100
-
2022-08-19
Chambers Michael Andrew
BOUGHT
4,999,230
108.279
46,170
-
2022-06-02
Chambers Michael Andrew
ACQUIRED
-
-
4,908
-
2022-06-02
Boor Kathryn Jean
ACQUIRED
-
-
4,908
-
2022-06-01
Brown Ryan Edward
SOLD (Taxes)
-3,924.18
72.67
-54
SVP, General Counsel
2022-03-07
Barry Richard
ACQUIRED
-
-
2,953
-
2022-03-07
Ciambrone William
ACQUIRED
-
-
8,000
EVP
2022-03-07
Estepan Ian Michael
ACQUIRED
-
-
8,000
Chief Financial Officer

1–10 of 50

Douglas S. Ingram
840
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Products, net$ 207,774$ 166,911$ 607,836$ 433,676
Type of Revenue [Extensible List]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Collaboration$ 22,495$ 22,495$ 66,750$ 66,750
Total revenues230,269189,406674,586500,426
Cost and expenses:    
Cost of sales (excluding amortization of in-licensed rights)39,95223,444109,19065,305
Research and development216,707139,115663,286573,886
Selling, general and administrative104,78761,127330,943204,605
Settlement and license charges00010,000
Amortization of in-licensed rights178178535527
Total cost and expenses361,624223,8641,103,954854,323
Operating loss(131,355)(34,458)(429,368)(353,897)
Other (loss) income, net:    
(Gain) loss on contingent consideration, net[1]6,7007,2006,7007,200
Loss on debt extinguishment(125,441)0(125,441)0
Other expense, net(6,322)(20,649)(40,548)(52,362)
Gain from sale of Priority Review Voucher000102,000
Total other (loss) income, net(125,063)(13,449)(159,289)56,838
Loss before income tax expense (benefit)(256,418)(47,907)(588,657)(297,059)
Income tax expense (benefit)1,3202375,587(260)
Net loss(257,738)(48,144)(594,244)(296,799)
Other comprehensive loss:    
Unrealized (losses) gains on investments, net of tax(720)(22)(3,185)(23)
Total other comprehensive loss(720)(22)(3,185)(23)
Comprehensive loss$ (258,458)$ (48,166)$ (597,429)$ (296,822)
Net loss per share - basic and diluted$ (2.94)$ (0.60)$ (6.79)$ (3.72)
Net loss per share - basic and diluted$ (2.94)$ (0.60)$ (6.79)$ (3.72)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share87,62879,88087,46579,695
Weighted average number of shares of common stock used in computing basic and diluted net loss per share87,62879,88087,46579,695
[1]The gain on contingent consideration, net is related to the fair value adjustment of the regulatory-related contingent payments that are accounted for as derivatives. Please see Note 4, Fair Value Measurements for further details.

SRPT Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 1,038,624$ 2,115,869
Short-term investments1,033,8600
Accounts receivable201,509152,990
Inventory221,192186,212
Other current assets130,744149,028
Total current assets2,625,9292,604,099
Property and equipment, net181,005191,156
Intangible assets, net13,05714,239
Right of use assets43,03445,531
Other non-current assets293,124292,949
Total assets3,156,1493,147,974
Current liabilities:  
Accounts payable118,46176,741
Accrued expenses368,998271,697
Deferred revenue, current portion89,24489,244
Other current liabilities26,21315,051
Total current liabilities602,916452,733
Long-term debt1,542,7701,096,876
Lease liabilities, net of current portion35,22941,512
Deferred revenue, net of current portion507,494574,244
Contingent consideration36,90043,600
Other non-current liabilities011,000
Total liabilities2,725,3092,219,965
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and outstanding00
Common stock, $0.0001 par value, 198,000,000 shares authorized; 87,535,299 and 87,126,974 issued and outstanding at June 30, 2022, and December 31, 2021, respectively99
Additional paid-in capital4,235,0284,134,768
Accumulated other comprehensive loss, net of tax(3,205)(20)
Accumulated deficit(3,800,992)(3,206,748)
Total stockholders’ equity430,840928,009
Total liabilities and stockholders’ equity$ 3,156,149$ 3,147,974